Get the Stockscreener App
1.47
0.68%
-0.01
Gain Therapeutics Inc stock is traded at $1.47, with a volume of 229.63K.
It is down -0.68% in the last 24 hours and down -15.03% over the past month.
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.
See More
Previous Close:
$1.48
Open:
$1.48
24h Volume:
229.63K
Relative Volume:
0.87
Market Cap:
$44.20M
Revenue:
$210.70K
Net Income/Loss:
$-21.37M
P/E Ratio:
-1.3364
EPS:
-1.1
Net Cash Flow:
$-21.10M
1W Performance:
+0.00%
1M Performance:
-15.03%
6M Performance:
-39.00%
1Y Performance:
+49.79%
1-Day Range:
$1.45
$1.54
1-Week Range:
$1.43
$1.68
52-Week Range:
$0.89
$3.19
Gain Therapeutics Inc Stock (GANX) Company Profile
Name
Gain Therapeutics Inc
Sector
Industry
Phone
(301) 500-1556
Address
4800 HAMPDEN LANE, BETHESDA
Compare GANX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GANX
Gain Therapeutics Inc
|
1.47 | 53.41M | 210.70K | -21.37M | -21.10M | -1.10 |
|
VRTX
Vertex Pharmaceuticals Inc
|
375.71 | 93.98B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
550.11 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
435.63 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
636.80 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
287.78 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Gain Therapeutics Inc Stock (GANX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Dec-06-24 | Initiated | ROTH MKM | Buy |
| Aug-14-24 | Resumed | Oppenheimer | Outperform |
| Apr-12-21 | Initiated | BTIG Research | Buy |
| Apr-12-21 | Initiated | Oppenheimer | Outperform |
Gain Therapeutics Inc Stock (GANX) Latest News
Analyzing recovery setups for Gain Therapeutics Inc. investorsTrade Safety Report with Pattern Insights - Newser
What analysts say about Gain Therapeutics Inc. stock outlookFree ROI Driven Equity Selection With Safety - Newser
Is Gain Therapeutics Inc. forming a reversal patternFree Safe Entry Stock Watch Suggestions - Newser
Candlestick signals on Gain Therapeutics Inc. stock todayPrice Action Based Buy Zone Forecast - Newser
Has Gain Therapeutics Inc. found a price floorFree Buy Signal Based on Chart Analysis - Newser
Healthcare Stocks in Focus: Gainers and Losers in Friday's After-Market Session - AInvest
Why Gain Therapeutics Inc. stock attracts strong analyst attentionFree Safe Entry Stock Watch Suggestions - Newser
Using flow based indicators on Gain Therapeutics Inc.Free Technical Stock Breakout Predictions - Newser
Visualizing Gain Therapeutics Inc. stock with heatmapsConsistent Return Setup with Exit Strategy - Newser
Best data tools to analyze Gain Therapeutics Inc. stockGrowth Watchlist for Long Term Positioning - Newser
Gain Therapeutics, Inc. (NASDAQ:GANX) Receives $8.20 Average Target Price from Analysts - Defense World
Gain Therapeutics (GANX) Projected to Post Earnings on Thursday - Defense World
What makes Gain Therapeutics Inc. stock price move sharplyGrowth Summary Based on Market Positioning - Newser
What technical models suggest about Alaunos Therapeutics Inc.’s comebackWeekly Signal Report with Trend Summary - Newser
What is the dividend policy of Gain Therapeutics Inc. stockConsistent wealth multiplication - Jammu Links News
Should I hold or sell Gain Therapeutics Inc. stock in 2025Discover breakthrough investment opportunities - Jammu Links News
Is Gain Therapeutics Inc. a good long term investmentAchieve breakthrough financial results today - Jammu Links News
Is Gain Therapeutics Inc. stock overvalued or undervaluedMaximize returns with disciplined trading approaches - Jammu Links News
What catalysts could drive Gain Therapeutics Inc. stock higher in 2025Capitalize on high-yield stocks early - Jammu Links News
Evaluating Gain Therapeutics Inc. with trendline analysisPortfolio Review Summary with Five-Year Outlook - Newser
What are analysts’ price targets for Gain Therapeutics Inc. in the next 12 monthsHigh-velocity gains - Jammu Links News
How does Gain Therapeutics Inc. compare to its industry peersAccelerated capital growth - Jammu Links News
How does Gain Therapeutics Inc. generate profit in a changing economyConsistent triple returns - Jammu Links News
What are the latest earnings results for Gain Therapeutics Inc.Free Bull & Bear Market Updates - Jammu Links News
What is the risk reward ratio of investing in Gain Therapeutics Inc. stockMarket Forecast Updates That Work - Jammu Links News
RSI Reset May Fuel Rebound in Gain Therapeutics Inc.Smart Allocation Stock Pick Insights Gaining Interest - metal.it
Fibonacci Retracement Aligns with Support in Gain Therapeutics Inc.Market Surge Signal for Swing Traders Triggered - metal.it
Gain Therapeutics Inc Stock (GANX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.68%
0.41%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):